Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.34 |
| ▸ | TP53 | P04637 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.33 |
| ▸ | SMO | Q99835 | 3/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3666472 | 1.00 | LMNA (0.34) | LMNATP53TSHRMAPTSMN1; SMN2 | |
| SCHEMBL3669538 | 0.91 | CYP2D6 (0.35) | LMNATP53MAPTSMN1; SMN2ALK | |
| SCHEMBL3673977 | 0.91 | CYP2D6 (0.35) | LMNATP53MAPTSMN1; SMN2ALK | |
| SCHEMBL3665526 | 0.89 | MEN1 (0.33) | TP53MAPTMEN1KMT2ATHRB | |
| SCHEMBL3670216 | 0.84 | LTA4H (0.37) | LMNATSHRHPGDCYP2D6 | |
| SCHEMBL3673491 | 0.82 | TP53 (0.36) | TP53TSHRMAPTSMN1; SMN2HPGD | |
| SCHEMBL3670815 | 0.82 | TP53 (0.36) | TP53TSHRMAPTSMN1; SMN2HPGD | |
| SCHEMBL3666767 | 0.81 | USP14 (0.32) | MEN1KMT2ACYP2D6 | |
| SCHEMBL975515 | 0.80 | CYP2D6 (0.32) | LMNACYP2D6 | |
| SCHEMBL3666328 | 0.79 | BACE1 (0.36) | TSHRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851484-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851484-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-20080242695-A1 | Certain Chemical Entities, Compositions, and Methods | CYTOKINETICS, INC. | 2008-10-02 | — | — | US | disclosed |
| US-20080242695-A1 | Certain Chemical Entities, Compositions, and Methods | CYTOKINETICS, INC. | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242695-A1 | Certain Chemical Entities, Compositions, and Methods | TNNC1, TNNI3, TNNT2 | LMNA 391/4885TP53 723/4885TSHR 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.